Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has ...
Webull delivered one of its strongest quarters since going public — revenue accelerated to 55% YoY, trading-related revenue surged 64%, and the company posted $36.7M in adjusted operating profit, a ...
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of ...
Mean Target Price: $18.50 Median Target Price: $18.50 High/Low Range: $19.00 / $18.00 Number of Analysts: 2 Rating: Buy (1.00) — the strongest rating on the scale Analysts covering BULL see the stock ...
Webull (NASDAQ: BULL), owner of the Webull online investment platform, this week announced the global launch of its consolidated market data feed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results